HCPCS
J9041
1 unit = 0.1 mg
Phase 1
Identify what you're billing
Confirm route, regimen, BSA dose, and product (brand vs generic vs Boruzu) before billing.
SC vs IV route — the clinical and billing decision FDA label verified May 2026
Same J9041, same ASP, but different concentrations, different admin CPTs, and very different neuropathy outcomes.
Bortezomib was originally approved as IV bolus in 2003. The SC route was added to the FDA label in January 2012 after the MMY-3021 trial showed equivalent efficacy with approximately 50% less peripheral neuropathy (any grade) and lower rates of grade 3+ neuropathy. SC is now the preferred route per FDA label and NCCN MM/MCL guidelines.
| Subcutaneous (preferred) | IV bolus | |
|---|---|---|
| Reconstitution | 1.4 mL of 0.9% NaCl → 2.5 mg/mL | 3.5 mL of 0.9% NaCl → 1 mg/mL |
| Volume injected (1.3 mg/m², 1.92 m² pt) | ~1.0 mL SC | ~2.5 mL IV bolus |
| Admin CPT | 96401 (chemo SC, non-hormonal) | 96409 (chemo IV push, single substance) |
| Administration time | 3–5 seconds (SC injection) | 3–5 seconds (IV push) |
| Peripheral neuropathy (any grade) | ~38% (MMY-3021) | ~53% (MMY-3021) |
| Grade 3+ neuropathy | ~6% | ~16% |
| Injection site reactions | ~6% (mild, self-resolving) | N/A |
| HCPCS | J9041 (same) | J9041 (same) |
| Site rotation | Required — thigh / abdomen, alternate sides | Standard IV access |
Concentration error = 2.5× overdose risk. SC concentration is 2.5 mg/mL; IV
concentration is 1 mg/mL. If the SC reconstitution (2.5 mg/mL) is accidentally administered IV at the
same volume calculated for IV (1 mg/mL), the patient receives 2.5× the intended dose. Pharmacy and
nursing should confirm route on every dose; some institutions use route-specific labels and barcoded
product checks.
Same J9041 either way. The HCPCS code does not change with route. What changes is the
admin CPT (
96401 SC vs 96409 IV push) and the patient experience. If the
provider documents SC, bill 96401 — do not default to 96372
(therapeutic SC injection); bortezomib is anti-neoplastic and CPT classifies its admin under chemo codes.
Brand Velcade vs generic bortezomib vs Boruzu CMS Q2 2026 ASP
Three distinct products, three J-codes, three ASPs. Same active ingredient.
| Velcade (brand) | Bortezomib (generic) | Boruzu (premixed) | |
|---|---|---|---|
| HCPCS | J9041 | J9049 | J9054 |
| Manufacturer | Takeda (originally Millennium) | Hospira (Pfizer); other generics available | Eagle Pharmaceuticals |
| Form | Lyophilized powder, requires reconstitution | Lyophilized powder, requires reconstitution | Premixed solution — ready to use |
| Vial | 3.5 mg single-dose vial | 3.5 mg single-dose vial | Premixed; no reconstitution required |
| Routes | SC or IV bolus | SC or IV bolus | Per Boruzu label |
| Q2 2026 ASP+6% | $2.253 / 0.1 mg unit | $1.259 / 0.1 mg unit | Verify CMS quarterly file |
| Cost vs brand | Reference | ~44% cheaper | Premium for convenience |
| Reconstitution time | ~3–5 min + verify concentration | ~3–5 min + verify concentration | None — pull and inject |
| Pharmacy error risk | Concentration error (SC 2.5 mg/mL vs IV 1 mg/mL) | Concentration error (same as Velcade) | Lower — no reconstitution step |
| Payer preference (typical) | Disfavored on cost | Often preferred on cost | Niche; convenience-driven |
Generic J9049 is preferred by most commercial payers. UHC, Aetna, and large BCBS plans
have moved bortezomib to a generic-preferred policy in oncology medical-drug coverage. Branded Velcade
(J9041) often requires step-therapy failure of generic J9049 unless there's a documented intolerance,
contraindication, or supply issue. Check the specific plan policy at PA submission — do not assume
brand will be approved without justification.
All three share the 0.1 mg unit basis. Whether you bill J9041, J9049, or J9054, 1 unit
equals 0.1 mg of bortezomib. A 2.5 mg dose is 25 units regardless of which product is administered.
Proteasome inhibitor class — where Velcade fits NCCN verified May 2026
Three proteasome inhibitors in MM care; only Velcade is first-generation. Coding and benefit pathway differ.
| Drug | HCPCS / Benefit | Generation / Mechanism | Route / Schedule | Typical use |
|---|---|---|---|---|
| Velcade (bortezomib, brand) | J9041 (medical) |
1st-gen reversible boronic acid PI | SC or IV bolus; weekly or twice-weekly per cycle | NDMM (transplant-eligible + ineligible), R/R MM, MCL combo |
| Bortezomib generic | J9049 (medical) |
1st-gen reversible boronic acid PI | SC or IV bolus; same as Velcade | Generic-preferred substitute for Velcade |
| Boruzu (bortezomib premixed) | J9054 (medical) |
1st-gen reversible boronic acid PI | Premixed solution; no reconstitution | Workflow-driven choice; same indications |
| Kyprolis (carfilzomib) | J9047 (medical) |
2nd-gen irreversible epoxyketone PI; more potent | IV infusion 10–30 min; twice-weekly or weekly | R/R MM combos; less neuropathy but more cardiac AEs |
| Ninlaro (ixazomib) | Pharmacy benefit — oral capsule (no J-code) | 1st-gen reversible boronic acid PI; oral | Oral once-weekly; days 1, 8, 15 of 28-day cycle | R/R MM combos; convenience over IV/SC |
Cross-link: See Kyprolis (J9047) for the second-generation
proteasome inhibitor option. Also see Darzalex (J9145) and
Empliciti (J9176) for the monoclonal antibody combo partners commonly paired
with bortezomib in MM regimens.
Class is not interchangeable for billing. Each PI has its own J-code, ASP, and PA
criteria. Switching between Velcade and Kyprolis is a regimen change that requires fresh PA in most
plans. Ninlaro is a pharmacy-benefit oral, not a medical-benefit injectable — coverage falls under
the pharmacy formulary, not the medical drug policy.
Dosing by regimen NCCN MM v.2.2026 / FDA label
All bortezomib regimens use 1.3 mg/m² SC; cycle length and dosing days vary by clinical scenario.
| Setting / Regimen | Dose | Schedule | Cycle length | Notes |
|---|---|---|---|---|
| NDMM, transplant-eligible (VRd, VTD) | 1.3 mg/m² SC | Days 1, 4, 8, 11 (twice weekly × 2 weeks) | 21 days (3 weeks) | Induction; usually 4–6 cycles pre-transplant |
| NDMM, transplant-ineligible (VMP) | 1.3 mg/m² SC | Cycles 1–4: days 1, 4, 8, 11, 22, 25, 29, 32. Cycles 5–9: days 1, 8, 22, 29 | 42 days (6 weeks) | + melphalan + prednisone; cycles taper to weekly |
| NDMM, transplant-ineligible (RVd-lite) | 1.3 mg/m² SC | Days 1, 8, 15, 22 (weekly × 4 weeks) | 35 days (5 weeks) | Once-weekly; better tolerability in older / frail patients |
| R/R MM (Vd, KPd, etc.) | 1.3 mg/m² SC | Days 1, 4, 8, 11 (twice weekly × 2 weeks) | 21 days | Similar to NDMM induction; combo dependent |
| Mantle cell lymphoma 1L (with R-CHP) | 1.3 mg/m² SC | Day 1 of each R-CHP cycle | 21 days | Single bortezomib dose per cycle in combo regimen |
BSA-based unit math — convert mg to 0.1 mg units
| Patient BSA | Dose at 1.3 mg/m² | J9041 units billed | Vial usage | JW waste units |
|---|---|---|---|---|
| 1.5 m² | 1.95 mg | 20 (round to 0.1 mg) | 1 × 3.5 mg vial | ~15 units (1.55 mg) |
| 1.7 m² | 2.21 mg | 22 | 1 × 3.5 mg vial | ~13 units (1.29 mg) |
| 1.8 m² | 2.34 mg | 23 | 1 × 3.5 mg vial | ~12 units |
| 1.92 m² (avg) | 2.50 mg | 25 | 1 × 3.5 mg vial | 10 units (1.0 mg) |
| 2.0 m² | 2.60 mg | 26 | 1 × 3.5 mg vial | 9 units (0.9 mg) |
| 2.2 m² | 2.86 mg | 29 | 1 × 3.5 mg vial | 6 units (0.64 mg) |
Worked example — NDMM transplant-eligible (VRd induction), 1.92 m² patient
# Per-dose math (1.3 mg/m² × 1.92 m² = 2.5 mg)
Drug administered: 2.5 mg SC
J9041 units billed: 25 (2.5 mg × 10 = 25 units of 0.1 mg)
Modifier: JW for waste (3.5 mg vial − 2.5 mg administered = 1.0 mg discarded = 10 units)
Admin CPT: 96401 (chemo SC)
# Per 21-day cycle (4 doses: days 1, 4, 8, 11)
Total drug units administered: 100 (4 × 25)
Total waste units: 40 (4 × 10)
Drug cost (Q2 2026 ASP+6%, J9041): 100 × $2.253 = $225.30 drug-only per cycle
# Compare with generic J9049 (~44% cheaper)
100 units × $1.259 = $125.90 — saves ~$99/cycle
Over 6 induction cycles: ~$600 brand-vs-generic delta on bortezomib alone
Drug administered: 2.5 mg SC
J9041 units billed: 25 (2.5 mg × 10 = 25 units of 0.1 mg)
Modifier: JW for waste (3.5 mg vial − 2.5 mg administered = 1.0 mg discarded = 10 units)
Admin CPT: 96401 (chemo SC)
# Per 21-day cycle (4 doses: days 1, 4, 8, 11)
Total drug units administered: 100 (4 × 25)
Total waste units: 40 (4 × 10)
Drug cost (Q2 2026 ASP+6%, J9041): 100 × $2.253 = $225.30 drug-only per cycle
# Compare with generic J9049 (~44% cheaper)
100 units × $1.259 = $125.90 — saves ~$99/cycle
Over 6 induction cycles: ~$600 brand-vs-generic delta on bortezomib alone
Round to the nearest 0.1 mg. CMS expects billed units in whole 0.1 mg increments. A
2.34 mg administered dose bills as 23 units (not 23.4). Pharmacy can prepare to the nearest 0.1 mg with
the 2.5 mg/mL SC concentration; document the actual dose given to support both administered and JW waste
units.
NDC reference FDA NDC Directory verified May 2026
| Product | NDC (10/11-digit) | Package | Use |
|---|---|---|---|
| Velcade (Takeda, brand) | 63020-049-01 / 63020-0049-01 |
3.5 mg single-dose vial — 1 vial / carton | Branded reference product (J9041) |
| Bortezomib (Hospira, generic) | Multiple — verify on label | 3.5 mg single-dose vial — 1 vial / carton | Generic substitute (J9049) |
| Boruzu (Eagle, premixed) | Per Boruzu prescribing info | Premixed solution — no reconstitution | Workflow-driven (J9054) |
NDC must match product administered. If pharmacy substituted generic bortezomib but the
claim went out with the Velcade NDC and J9041, the claim is wrong on both axes. Reconcile pharmacy
dispensing log to billed J-code and NDC every cycle.
Phase 2
Code the claim
Chemo admin codes apply (96401 SC / 96409 IV push). Do NOT use 96372.
Administration codes CPT verified May 2026
Bortezomib is anti-neoplastic; CPT classifies its administration under chemo codes regardless of clinical setting.
| Code | Description | When to use |
|---|---|---|
96401 |
Chemotherapy administration, subcutaneous or intramuscular; non-hormonal anti-neoplastic | Primary code for SC bortezomib (most common). Bill once per encounter. |
96409 |
Chemotherapy administration, IV push technique, single or initial substance/drug | For IV bolus route only (less common). Do not pair with 96413/96365. |
96372 |
Therapeutic SC/IM injection (non-anti-neoplastic) | NOT appropriate for bortezomib. CPT classifies anti-neoplastic SC admin under 96401. Using 96372 results in materially lower reimbursement and may trigger payer audits. |
96365 |
Therapeutic IV infusion (non-chemo) | NOT appropriate for bortezomib. Bortezomib is given IV bolus, not infusion, and is classified as chemo admin per CPT. |
96402 |
Chemotherapy admin, SC/IM; hormonal anti-neoplastic | Not bortezomib (bortezomib is non-hormonal). Use 96401. |
96401 chemo SC, NOT 96372. The most common bortezomib billing error after the 0.1 mg
unit-basis confusion is using
96372 (therapeutic SC injection) for bortezomib. Bortezomib is
anti-neoplastic; CPT requires the chemo SC administration code 96401. 96401
reimburses materially higher and is the correct classification per AMA CPT. Using 96372 for
chemo administration is a known audit target.
One admin code per encounter. Bortezomib SC is a single injection — bill 96401
once per dose date. Combo regimens with other chemo on the same day follow CPT rules for sequencing
codes (96413 for primary IV chemo + 96367 for additional, or 96401 for additional SC, etc.). Document
each agent's route and time to support code selection.
Modifiers CMS verified May 2026
JW — required for waste documentation (BSA dosing produces waste)
Bortezomib is supplied in 3.5 mg single-dose vials. BSA-based dosing at 1.3 mg/m² rarely uses the full vial — a typical 1.92 m² patient receives 2.5 mg, leaving 1.0 mg discarded. JW modifier reports the discarded portion of a single-dose vial. Bill JW on a separate claim line with the wasted units.
JZ — required when no waste occurs (rare in adult bortezomib)
Effective July 1, 2023, CMS requires JZ on all single-dose container claims when no drug is discarded. JZ rarely applies to bortezomib because BSA-calculated doses almost never exactly equal 3.5 mg. However, if a patient's BSA produces a dose of exactly 3.5 mg (BSA = 2.69 m²), bill JZ. One of JZ or JW must be on every J9041 claim.
Modifier 25 — same-day E/M
Use modifier 25 on the E/M code when a significant, separately identifiable evaluation and management service is performed on the same day as the injection. Routine pre-administration assessment is bundled into 96401.
340B modifiers (JG, TB)
For 340B-acquired bortezomib, follow your MAC's current 340B modifier policy. JG (drug or biological acquired with 340B drug pricing program discount) typically applies to OPPS settings; TB applies to certain other 340B contexts. Check the most recent CMS 340B billing instructions and your MAC's policy.
Common error: missing JW on a vial that was clearly partial. If a 1.5 m² patient
received 1.95 mg from a 3.5 mg vial, ~1.55 mg was discarded. CMS expects the JW line. Forgetting it
either leaves money on the table (waste is reimbursable) or, if the JZ box is checked instead, creates
a documentation conflict with pharmacy logs.
ICD-10-CM by indication FY2026 verified May 2026
Multiple myeloma is the dominant indication; mantle cell lymphoma is the secondary indication.
| Indication | ICD-10 family | Specifics | Notes |
|---|---|---|---|
| Multiple myeloma (MM) | C90.0x |
C90.00 not having achieved remission; C90.01 in remission; C90.02 in relapse |
Use most specific 5th character per chart documentation |
| Plasma cell leukemia | C90.1x |
Subtype of MM; rare | NCCN MM guidelines apply |
| Solitary plasmacytoma | C90.3x |
Off-label for bortezomib monotherapy; check NCCN | PA likely required for off-label |
| Mantle cell lymphoma (MCL) | C83.1x |
C83.10 unspecified; C83.11 nodes head/face/neck; C83.12 intrathoracic; C83.13 intra-abdominal; C83.14 axilla/upper limb; C83.15 inguinal/lower limb; C83.16 intrapelvic; C83.17 spleen; C83.18 multiple sites; C83.19 extranodal/solid organ |
1L combo with R-CHP; bortezomib is the V in VR-CHP |
ICD-10 alone is rarely sufficient for PA approval. Most payers require ICD-10
plus line of therapy plus combo regimen documentation (e.g., VRd 1L, VMP for
transplant-ineligible NDMM, or VR-CHP for MCL 1L). Include the regimen acronym and prior therapies in the
PA submission.
Site of care & place of service Verified May 2026
Bortezomib SC is brief (3–5 second injection) and pairs efficiently with office and ASC visits. Most major commercial payers prefer non-HOPD settings for proteasome inhibitors. UHC and Aetna run site-of-care UM that steers oncology biologics out of hospital outpatient after initial cycles.
| Setting | POS | Claim form | Payer steering |
|---|---|---|---|
| Physician oncology office | 11 | CMS-1500 / 837P | Preferred by commercial UM |
| Ambulatory infusion suite (AIC) | 49 | CMS-1500 / 837P | Preferred by commercial UM |
| Oncology ASC | 24 | CMS-1500 / 837P | Acceptable |
| Hospital outpatient (on-campus) | 22 | UB-04 / 837I | Disfavored after first 3 months |
| Hospital outpatient (off-campus PBD) | 19 | UB-04 / 837I | Disfavored after first 3 months |
| Patient home | 12 | CMS-1500 (with home infusion) | Possible (SC injection); rare for oncology PI |
SC bortezomib is a candidate for office-based delivery. Unlike infused biologics, the
SC route doesn't require chair time. Practices with high MM volume often centralize bortezomib SC in a
single office workflow to avoid AIC scheduling friction. Verify your payer's site-of-care policy and
place-of-service preferences before shifting workflows.
Claim form field mapping Takeda OnePath 2025
From Takeda Velcade billing & coding guide and CMS Manual.
| Information | CMS-1500 box | Notes |
|---|---|---|
| NPI | 17b | Rendering provider |
| NDC qualifier + 11-digit NDC + UoM + qty | 24A shaded area | N4 + carton NDC + ML + total volume reconstituted |
| HCPCS J9041 + JZ or JW | 24D (drug line, administered) | JW typical for BSA-dosed bortezomib (waste) |
| Drug units (administered) | 24G | 0.1 mg increments — multiply mg × 10 |
| HCPCS J9041 + JW (waste line) | 24D (drug line, waste) | Separate line for discarded units |
| CPT 96401 (admin) | 24D (admin line) | SC chemo, non-hormonal — not 96372 |
| ICD-10 | 21 | C90.0x for MM, C83.1x for MCL |
| PA number | 23 | Required by all major payers for J9041 brand |
Phase 3
Get paid
Generic J9049 is preferred by most payers; brand J9041 needs justification.
Payer policy snapshot Reviewed May 2026
All major payers require PA. Brand Velcade (J9041) typically requires step-therapy through generic bortezomib (J9049).
| Payer | PA? | Brand vs generic stance | Combo / regimen requirements |
|---|---|---|---|
| UnitedHealthcare Oncology Med Coverage Policy |
Yes | Generic J9049 preferred; brand J9041 requires justification (intolerance, supply, contraindication) | MM/MCL pathology + regimen-specific docs (e.g., VRd 1L, VMP transplant-ineligible). Concurrent PA on combo agents (lenalidomide REMS for VRd). |
| Aetna CPB + Medical Drug policies |
Yes | Generic-preferred for bortezomib in oncology medical drug policy | FDA-labeled indications + NCCN compendium; line of therapy required |
| BCBS plans Vary by plan |
Yes | Most plans generic-preferred; some still allow brand at parity | Generally aligned with NCCN MM/MCL guidelines |
| Medicare Advantage | Plan-dependent | Often follows commercial generic-preferred logic | NCD/LCD compliance + indication-specific docs |
Combo-agent PA chains
Bortezomib is rarely used as monotherapy. Combo agents have their own PA pathways:
- Lenalidomide (Revlimid) — pharmacy benefit, REMS-enrolled, separate PA
- Dexamethasone — usually no PA required
- Daratumumab (Darzalex J9145 / Darzalex Faspro J9144) — medical benefit, separate PA
- Cyclophosphamide — medical benefit, generally no PA
- Melphalan — medical benefit, plan-specific
Submit all combo PAs in parallel; a hold on lenalidomide REMS enrollment will block the entire VRd regimen even if bortezomib is approved.
Medicare reimbursement CMS Q2 2026 (live)
Quarterly ASP from CMS Part B Drug Pricing File. Refreshes automatically each quarter.
Q2 2026 payment snapshot — J9041 (branded Velcade)
Effective April 1 – June 30, 2026 · Based on 4Q25 ASP submissions
ASP + 6%
$2.253
per 0.1 mg unit / Q2 2026
Per mg
$22.53
10 units × ASP+6%
Typical 2.5 mg dose
$56.33
25 units × ASP+6%
Annualized cost (drug-only, Q2 2026 ASP+6%, brand J9041):
VRd induction (4 doses/cycle × 6 cycles, 1.92 m² pt) ≈ $1,352 bortezomib
component over the induction phase. Maintenance regimens (e.g., VMP cycles 5–9) add ~$900/cycle.
After ~2% sequestration: actual paid ≈ ASP + 4.3%. Generic J9049 reduces these costs ~44%.
Coverage
No NCD specific to bortezomib. Coverage falls under MAC LCDs for biologics + the generic drug-coverage framework. All MACs cover J9041 and J9049 for FDA-approved on-label MM and MCL indications with appropriate ICD-10 documentation.
Code history
- J9041 — permanent code, "Injection, bortezomib, 0.1 mg" (originator Velcade)
- J9049 — bortezomib generic injection (Hospira)
- J9054 — Boruzu (bortezomib premixed solution, Eagle Pharmaceuticals)
Patient assistance — Takeda OnePath Takeda verified May 2026
- Takeda OnePath / Takeda Patient Support: 1-866-861-1750 — benefits investigation, prior authorization assistance, appeal support, copay enrollment
- Velcade Co-pay Program: commercial copay support; eligible commercially-insured patients — $0 first dose with ongoing copay assistance (excludes Medicare, Medicaid, federal program patients)
- Takeda Patient Assistance Foundation: free product for uninsured / underinsured patients meeting income requirements (501(c)(3) administered)
- Foundations (Medicare patients): refer to PAN Foundation, HealthWell, CancerCare, Leukemia & Lymphoma Society Co-Pay Assistance — verify open MM funds quarterly
- Web: takedaonepath.com / velcade.com
Need to model what a specific patient will actually pay after copay assistance, deductible, coinsurance,
and OOP max? Run a CareCost Estimate — J9041 pre-loaded.
Phase 4
Fix problems
Peripheral neuropathy management drives dose decisions; billing errors drive denials.
Peripheral neuropathy — the dose-limiting toxicity FDA label verified May 2026
Peripheral neuropathy (PN) is the dominant dose-limiting toxicity. Sensory and motor
neuropathy occur in a substantial proportion of patients on bortezomib; severe PN drives most dose
reductions and discontinuations. Switching from IV to SC reduces incidence by approximately 50% with
equivalent efficacy — SC route is now preferred per FDA label and NCCN guidelines.
NCI CTCAE-graded PN dose modifications (per FDA label)
| PN severity (CTCAE) | Recommended dose modification |
|---|---|
| Grade 1 (paresthesia, no pain, no functional impact) | No change |
| Grade 1 with pain OR Grade 2 (interfering with function but not ADLs) | Reduce to 1.0 mg/m² |
| Grade 2 with pain OR Grade 3 (interfering with ADLs) | Hold until resolved to ≤ Grade 1, then resume at 0.7 mg/m² weekly |
| Grade 4 (life-threatening; permanent sensory loss) | Discontinue bortezomib |
Other key Warnings & Precautions (no formal boxed warning)
- Hypotension — risk of orthostatic hypotension; monitor BP, hydrate
- Cardiac toxicity — new or worsening heart failure; monitor symptoms
- Pulmonary toxicity — rare but severe; pneumonitis, ARDS reported
- Posterior reversible encephalopathy syndrome (PRES) — rare; MRI if symptoms (headache, seizure, vision change, altered mental status)
- GI events — nausea, diarrhea, constipation, ileus
- Thrombocytopenia and neutropenia — cyclic; monitor CBC; hold or reduce per label
- Tumor lysis syndrome — high-burden disease; monitor electrolytes, urate, hydration
- Herpes zoster reactivation — acyclovir prophylaxis recommended throughout treatment
- Hepatic events — LFT monitoring; dose modifications for moderate/severe hepatic impairment
- Embryo-fetal toxicity — contraception required for both partners during treatment
Acyclovir prophylaxis is the standard. Most centers initiate acyclovir 400–800 mg
BID at the start of bortezomib therapy and continue throughout treatment + a few weeks after the last
dose. Herpes zoster reactivation is a known class effect of proteasome inhibitors.
Common denials & how to fix them
| Denial reason | Common cause | Fix |
|---|---|---|
| Units 10× too low (underbilled) | Billed mg as units instead of 0.1 mg increments | Resubmit with corrected units (mg × 10). 2.5 mg = 25 units, not 2.5 units. |
| Brand denied; generic preferred | J9041 billed without step-therapy through J9049 | Submit J9049 (generic) unless documented intolerance/contraindication/supply issue. If brand medically necessary, include justification in PA. |
| Wrong admin code (96372) | Therapeutic SC injection billed instead of chemo SC | Resubmit with 96401. Bortezomib is anti-neoplastic per CPT classification. |
| Missing JW for waste | Partial-vial dose without JW line | Add JW line for discarded units. Most BSA doses produce waste with the 3.5 mg vial. |
| Missing JZ on full-vial dose | Single-dose vial claim without JZ when no waste | Add JZ if BSA happens to equal exactly 3.5 mg. Required since 7/1/2023. |
| NDC mismatch with J-code | Pharmacy dispensed generic but claim went out with Velcade NDC + J9041 | Reconcile pharmacy log to claim. Generic = J9049 + matching NDC; brand = J9041 + 63020-049-01. |
| Combo regimen not documented | ICD-10 alone submitted without VRd / VMP / VR-CHP regimen | Submit complete clinical history: line of therapy, combo agents, prior therapies, response. |
| Lenalidomide REMS hold | VRd regimen blocked because lenalidomide PA not approved | Submit lenalidomide REMS + PA in parallel with bortezomib PA. Both must clear before VRd starts. |
| Site of care (HOPD) | HOPD administration after first 3 months on commercial plan with site-of-care UM | Move to office (POS 11) or AIC (POS 49). SC bortezomib pairs efficiently with office workflow. |
| Duplicate J9041 + J9049 lines | Brand and generic both billed in same encounter | Bill only the product administered. Reconcile to pharmacy dispensing. |
Frequently asked questions
What is the HCPCS code for Velcade?
Velcade (bortezomib) is billed under HCPCS J9041 — "Injection, bortezomib,
0.1 mg." 1 unit = 0.1 mg (NOT 1 mg per unit), which is unusual and a frequent biller
error trap. A standard 2.5 mg dose is 25 units. Generic bortezomib (Hospira) bills under
J9049; premixed Boruzu (Eagle) bills under J9054; all three share the 0.1 mg
unit basis.
How many units do I bill for a 2 mg Velcade dose?
A 2 mg dose = 20 units of J9041 (because 1 unit = 0.1 mg). Multiply mg
administered by 10. Single-dose 3.5 mg vials produce waste with most BSA-calculated doses — bill
the JW modifier line for the discarded portion.
Should Velcade be given subcutaneously or IV?
Subcutaneous (SC) is preferred per FDA label and NCCN guidelines. SC reduces incidence
of peripheral neuropathy by approximately 50% compared to IV bolus, with equivalent efficacy. SC is
reconstituted to 2.5 mg/mL (1.4 mL diluent in 3.5 mg vial); IV uses 1 mg/mL (3.5 mL diluent). Admin
codes differ: 96401 (chemo SC) for SC, 96409 (chemo IV push) for IV.
What administration CPT do I use for Velcade?
CPT 96401 — "Chemotherapy administration, subcutaneous or intramuscular; non-hormonal
anti-neoplastic" — for the SC route (most common). Do NOT use 96372 (therapeutic SC
injection); bortezomib is anti-neoplastic and CPT classifies its administration under chemo codes. For
IV bolus, use 96409 (chemo IV push, single substance).
What is the Medicare reimbursement for J9041?
For Q2 2026, the Medicare Part B payment limit for J9041 (branded Velcade) is $2.253 per 0.1 mg unit (= $22.53 per mg, ASP + 6%). A typical 2.5 mg dose reimburses at approximately $56.33 per administration. Generic bortezomib J9049 reimburses at $1.259 per 0.1 mg unit — approximately 44% cheaper than branded Velcade. Many payers prefer J9049.
What's the difference between Velcade (J9041), Boruzu (J9054), and generic bortezomib (J9049)?
Same active ingredient (bortezomib), different products and J-codes. Velcade (J9041) is the
originator from Takeda — lyophilized powder. Generic bortezomib (J9049, Hospira) is
the AB-rated generic, ~44% cheaper. Boruzu (J9054, Eagle) is a premixed solution that
skips reconstitution. All three share the 0.1 mg unit basis. Most payers prefer J9049 over J9041 for cost.
Is peripheral neuropathy a problem with Velcade?
Yes — peripheral neuropathy (sensory and motor) is the dose-limiting toxicity of bortezomib. Switching from IV to SC reduces incidence by approximately 50% with equivalent efficacy. SC route is now preferred per FDA label and NCCN. Beyond neuropathy, the FDA label warns about hypotension, cardiac toxicity, pulmonary toxicity, PRES, GI events, thrombocytopenia, neutropenia, tumor lysis syndrome, and herpes zoster reactivation (acyclovir prophylaxis recommended). No formal boxed warning.
What ICD-10 codes do I use for Velcade?
Multiple myeloma is the dominant indication: C90.00 (not in remission), C90.01
(in remission), C90.02 (in relapse). Mantle cell lymphoma uses the C83.1x family
(e.g., C83.10 unspecified, C83.11 nodes head/face/neck, etc.). Submit
the most specific code supported by encounter documentation. Most payers also require line of therapy and
regimen acronym (VRd, VMP, VR-CHP) in the PA.
Reference
Sources & methodology
Every claim on this page is sourced. Methodology and review history below.
Source documents
- Takeda — Velcade HCP page
- DailyMed — VELCADE (bortezomib) Prescribing Information
- Takeda OnePath — Patient Support
- CMS — Medicare Part B Drug ASP Pricing File
- SEER CanMED — HCPCS J9041 reference
- NCCN Clinical Practice Guidelines — Multiple Myeloma + B-cell Lymphomas (MCL)
- UnitedHealthcare — Oncology Medication Clinical Coverage Policy
- Aetna — Oncology Clinical Policy Bulletins (medical drug)
- FDA National Drug Code Directory
- AMA CPT — chemotherapy administration codes (96401, 96409)
- Eagle Pharmaceuticals — Boruzu (J9054) prescribing info
About this page
We maintain this page as a living reference. Medicare ASP pricing is bound to our underlying CareCost data layer and refreshes automatically when CMS publishes new quarterly files. Coding and policy content is reviewed at least quarterly and updated whenever a source document changes.
Found an error? Email hello@carecostestimate.com.
Refresh cadence
| Element | Cadence | How it's refreshed |
|---|---|---|
| Medicare ASP pricing (J9041, J9049, J9054) | Quarterly | Auto-bound to CareCost ASP layer; updates on CMS file release. |
| Brand vs generic ASP delta | Quarterly | Recomputed from CMS Q-file each quarter. |
| Payer policies (UHC, Aetna, BCBS) | Semi-annual | Manual review against published payer policy documents. |
| HCPCS / CPT / modifier rules | Annual | Reviewed against CMS HCPCS quarterly files and AMA CPT releases. |
| NDC, dosing, FDA label, regimen list | Event-driven | Tied to manufacturer document version + FDA label revision date + NCCN MM/MCL updates. |
Reviewer
Pending SME review. This page is staff-authored from primary sources (FDA, CMS,
Takeda, NCCN, payer documents — all linked above). Editorial review in progress. Until that review is complete, treat this as a draft reference and verify each cited
source for high-stakes claims.
Change log
- — Initial publication. ASP data: Q2 2026 (J9041 brand $2.253/0.1 mg; J9049 generic $1.259/0.1 mg). Manufacturer source: Takeda OnePath 2025. FDA label most recent revision. NCCN MM v.2.2026 + B-cell Lymphomas (MCL) regimens. Brand/generic/Boruzu comparison + proteasome inhibitor class context (Kyprolis, Ninlaro).
Methodology
Every claim on this page is sourced inline. Pricing reflects the current CMS Part B Drug ASP Pricing File. Payer policies are read directly from each payer's published medical/pharmacy policy documents. Indications and dosing are verified against the current FDA label revision and NCCN compendium. We do not paraphrase from billing-software vendor blogs.